Linarin attenuates hyperuricemic nephropathy by modulating Nrf2/Keap1 and TLR4/NF-κB signaling pathways: Linarin attenuates hyperuricemic nephropathy

Phytomedicine. 2025 Apr:139:156440. doi: 10.1016/j.phymed.2025.156440. Epub 2025 Jan 29.

Abstract

Background: Hyperuricemia (HUA) can lead to hyperuricemic nephropathy (HN) as a result of prolonged uric acid (UA) supersaturation, primarily characterized by excessive inflammation and oxidative stress. In clinical practice, the absence of specific drugs for HN treatment necessitates the use of urate-lowering drugs, despite their lack of reno-protective properties. Linarin, the principal pharmacological constituent of Chrysanthemum indicum L. (C. indicum L.), exhibits diverse bioactivities, including anti-inflammatory, antioxidant, and nephroprotective effects. However, there have been no reports on linarin's ability to mitigate HN, and the underlying mechanisms remain unexplored.

Purpose: This study aimed to investigate the mechanisms of linarin on ameliorating HN, with a particular emphasis on oxidative stress and inflammatory pathways.

Methods: A HUA mouse model was developed using male ICR mice treated with hypoxanthine and potassium oxonate. Additionally, an adenosine-induced hyperuricemic cell model was established in NRK-52E cells. Following linarin treatment, serum UA levels and renal function parameters were assessed. The expression of proteins associated with UA production and excretion, oxidative stress, inflammation, and apoptosis was evaluated using western blot, immunohistochemical, and immunofluorescence analyses. Furthermore, Nrf2 knockout mice and Nrf2 inhibitor ML385 were utilized to investigate the mechanism of linarin on improving HN.

Results: Linarin significantly decreased the serum UA levels, inhibited XO activity and regulated UA transporter in the HUA mice. Moreover, linarin reversed the renal index, serum BUN and Cr levels, along with the expression levels of KIM-1, apoptosis-related molecules. Additionally, linarin obviously reduced the levels of TNF-α, IL-1β and IL-6, and alleviated renal inflammatory via suppressing the TLR4, p-NF-κB and p-IκBα levels. Furthermore, linarin was able to reverse the levels of SOD and MDA, and the expression of Nrf2, Keap1, NQO1, and HO-1 to mitigate oxidative stress both in vitro and in vivo. Inhibition of Nrf2 further confirmed that the renoprotective effect of linarin was linked to the activation of Nrf2.

Conclusion: This study is the first to propose linarin as a potential natural compound for alleviating HN by modulating the Nrf2/Keap1 and TLR4/NF-κB signaling pathways, providing a promising strategy for HN.

Keywords: Hyperuricemia; Hyperuricemic nephropathy; Linarin; Nrf2; TLR4/NF-κB; Xanthine oxidase.

MeSH terms

  • Animals
  • Cell Line
  • Chrysanthemum / chemistry
  • Disease Models, Animal
  • Glycosides
  • Hyperuricemia* / complications
  • Hyperuricemia* / drug therapy
  • Kelch-Like ECH-Associated Protein 1 / metabolism
  • Kidney / drug effects
  • Kidney Diseases* / drug therapy
  • Kidney Diseases* / etiology
  • Kidney Diseases* / metabolism
  • Male
  • Mice
  • Mice, Inbred ICR
  • NF-E2-Related Factor 2 / metabolism
  • NF-kappa B / metabolism
  • Oxidative Stress / drug effects
  • Rats
  • Signal Transduction / drug effects
  • Toll-Like Receptor 4 / metabolism
  • Uric Acid / blood

Substances

  • NF-E2-Related Factor 2
  • Kelch-Like ECH-Associated Protein 1
  • NF-kappa B
  • Toll-Like Receptor 4
  • Keap1 protein, mouse
  • Nfe2l2 protein, mouse
  • linarin
  • Tlr4 protein, mouse
  • Uric Acid
  • Glycosides